FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Amgen news from FiercePharma

News

Enbrel gets black-box infection warning

Enbrel's new black box is now official. Wyeth and Amgen have put the final touches on a Read more...

AAMC: Ban pharma gifts at med schools

Will all medical schools bar the door to pharma giveaways? The Association of American Medical Colleges hopes so. After two years of study, the influential group drafted a policy that would ban drug Read more...

AZ, Amgen earnings flat; Shire sales leap

It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring Read more...

Emerging markets drive global growth

Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...

Arms twisted, pharma promises disclosure

Pharma knows that self-regulation is the best kind. That's why 12 drug and device makers have promised Sen. Chuck Grassley that they are working on plans to disclose CME grants. You know, the money Read more...

Takeda offers $8.8B for Millennium

Takeda Pharmaceutical is placing an $8.8 billion bet on cancer meds. The Japanese drugmaker has offered $25 per share for Millennium Pharmaceuticals, which not only makes the lucrative blood-cancer Read more...
Tags: Velcade   Amgen   Actos   pipeline  

Roche appeals Mircera injunction

Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring Read more...

Grassley: Amgen doc rebates skyrocket

Another day, another Grassley letter. You'll recall that earlier this week, Sen. Chuck Grassley demanded documents from Amgen relating to the company's promotions of its anemia drugs. Now, Grassley Read more...
Tags: Aranesp   Amgen   Anemia  

ALSO NOTED: Takeda prevails in Actos patent suit; Analyst gets peek at Biovail founder's laptop;

> The U.S. Supreme court refused to reconsider an appeals court ruling that upheld Takeda's patent on its diabetes treatment Actos, a decision that keeps Alphapharm from launching a generic Read more...
Tags: Velcade   Amgen   GlaxoSmithKline  

SPOTLIGHT: Amgen pays CEO 29 percent less

It's a pay cut for Amgen Chairman and CEO Kevin Sharer (photo). His 2007 compensation dropped by nearly 29 percent to Read more...
Tags: Amgen  

Press Releases

FDA Receives New Data on Risks of Anemia Drugs

FDA Receives New Data on Risks of Anemia Drugs Consistent With Previous Data on Tumor Growth and Death The U.S. Food and Drug Administration (FDA) is reviewing new data from two studies that provide Read more...

PRESS RELEASE: Amgen Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Can

Amgen Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy SAN ANTONIO -- Amgen today Read more...

PRESS RELEASE: Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints

Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints Data Show Romiplostim Increased and Sustained Platelet Counts in Splenectomized Adult Patients with Immune Read more...

PRESS RELEASE: Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in Breast Cancer Patients

Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in Breast Cancer Patients THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen, Inc. (NASDAQ: AMGN - News) today announced that it had received Read more...

PRESS RELEASE: FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing

FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy Read more...

Get more Amgen coverage at: